Cytori Therapeutics, Inc. reported preclinical study results, which demonstrate the potential benefit of adipose-derived stem and regenerative cells (ADRCs) for the treatment of damaged intervertebral discs, evidenced by significantly increased disc tissue density and disc-specific extracellular matrix components at 12-months post treatment in a large animal model. The data were presented today at the 2008
Full Post: Cytori reports benefit of adipose-derived regenerative cells in spinal disc model
The U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee today voted unanimously to recommend approval of Bausch & Lomb’s besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis.
The company has developed this broad-spectrum, anti-infective drop specifically for ophthalmic use.
All new chemical entities such as besifloxacin, a fluoroquinolone, must be reviewed by an FDA advisory committee as part of the approvals review process for new drug applications.
“We are encouraged by this morning’s committee discussion and vote, and look forward to continue working with the FDA to gain final approval,” said Flemming Ornskov, M.D., M.P.H., corporate vice president and global president, Pharmaceuticals, Bausch & Lomb. “Our intent remains to bring this innovative product to market, beginning in the U.S., in 2009.”
http://www.bausch.com
--------------------------------------------------------------------------------------------
Related Posts:
Allergan, Inc. has announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve LATISSE (bimatoprost solution 0.03%) as a treatment for hypotrichosis (or reduced amount of hair) of the eyelashes. If approved, LATISSE would be the first and only FDA-approved pharmaceutical
Full Post: FDA Advisory Committee Unanimously Recommends Approval of LATISSE™ (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
Daiichi Sankyo Company, Limited and Eli Lilly and Company has confirmed that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009. Prasugrel is an investigational antiplatelet agent for the treatment of patients with acute coronary syndromes (ACS) who
Full Post: FDA to review prasugrel for acute coronary syndromes
Centocor, Inc., has announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab. The application, filed by Centocor in late 2007, seeks approval to market ustekinumab as a subcutaneous biologic therapy for the treatment of adult patients with chronic moderate to severe plaque
Full Post: FDA issues complete response to biologics license application for ustekinumab
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of
Full Post: Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy. The action letter includes proposed
Full Post: FDA issues complete response letter for SAPHRIS (asenapine) sublingual tablets in acute treatment of schizophrenia and bipolar disorder --------------------------------------------------------------------------------------------
